From Nasdaq: 2025-04-22 04:00:00

Stoke Therapeutics, Inc. (STOK) shares rose 12% to $8.61 on high volume, reversing a 5.6% loss in the past four weeks. Investors are optimistic about the progress of zorevunersen for Dravet syndrome treatment.

Expect quarterly loss of $0.37 per share and $10.64 million in revenue, up 152%. Earnings estimate revisions are down 333.8% in the last 30 days, affecting stock price movement.

XOMA Royalty (XOMA) rose 4.3% to $22.09. Consensus EPS estimate for XOMA is -$0.26, up 69.8% from last year. Zacks Rank of #3 (Hold) for XOMA Royalty in the Medical – Biomedical and Genetics industry.



Read more at Nasdaq: Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?